Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

Peer Review reports

Original Submission
8 Feb 2018	Submitted	Original manuscript
13 May 2018	Author responded	Author comments - Lilian SCHWARZ
Resubmission - Version 2
13 May 2018	Submitted	Manuscript version 2
Publishing
5 Jul 2018	Editorially accepted
24 Jul 2018	Article published	10.1186/s12885-018-4663-4

Back to article page